anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The safety and effectiveness of COMETRIQ in pediatric patients have not been studied.

Juvenile Animal Toxicity Data

Juvenile rats were administered cabozantinib daily at doses of 1 or 2 mg/kg/day from Postnatal Day 12 (comparable to less than 2 years in humans) through Postnatal Day 35 or 70. Mortalities occurred at doses equal and greater than 1 mg/kg/day (approximately 0.07 times the clinical dose of 140 mg/day based on body surface area). Hypoactivity was observed at both doses tested on Postnatal Day 22. Targets were generally similar to those seen in adult animals, occurred at both doses, and included the kidney (nephropathy, glomerulonephritis), reproductive organs, gastrointestinal tract (cystic dilatation and hyperplasia in Brunner’s gland and inflammation of duodenum; and epithelial hyperplasia of colon and cecum), bone marrow (hypocellularity and lymphoid depletion), and liver. Tooth abnormalities and whitening as well as effects on bones including reduced bone mineral content and density, physeal hypertrophy, and decreased cortical bone also occurred at all dose levels. Recovery was not assessed at the 2 mg/kg dose level (approximately 0.14 times the clinical dose of 140 mg based on body surface area) due to high levels of mortality. At the low dose level, effects on bone parameters were partially resolved but effects on the kidney and epididymis/testis persisted after treatment ceased.
1,147,371. 13-Phenyl-gonenes. MERCK & CO. Inc. 8 June, 1966 [15 June, 1965], No. 25563/66. Heading C2U. Novel compounds of the formulaµ (wherein R 1  is H or an aliphatic or cycloaliphatic hydrocarbon radical which may be substituted, an aryl or an aralkyl radical of at most 8 carbon atoms and Y is H or a saturated or unsaturated hydrocarbon or halogenated hydrocarbon radical of at most 3 carbon atoms) are prepared by the processes illustrated in the following reaction schemes (wherein R 2  is C 1-8  alkyl and TPY is tetrahydropyranyl). 17-Esters and -ethers are prepared by standard procedures from the 17-ols. The 13-phenylgonadienes have anti-androgenic activity and may be made up into pharmaceutical compositions for oral or parenteral administration with suitable carriers.
BACKGROUND: Radial access is the default approach in interventional cardiology. The Axiostat® surgical hemostatic dressing, using chitosan as its active component, has demonstrated potential in accelerating blood clotting. This study aims to assess the efficacy and the safety of the Axiostat® dressing in achieving hemostasis in patients undergoing transradial coronary angioplasty (TRCA).
METHODS: This prospective, single-center observational study, conducted in 2022, enrolled consecutive patients undergoing TRCA, with a target of 150 participants. The primary outcome was the success rate of radial artery hemostasis at 120 min, without bleeding necessitating immediate re-compression. The secondary outcome included Axiostat® performance at 24 h and 30 days Postprocedure.
RESULTS: The study was terminated prematurely for ethical and patient safety reasons, after inclusion of 41 consecutive TRCA patients due to an unexpectedly high radial artery thrombosis rate (19.5%, n = 8/41) observed 24 h Postprocedure. The success rate of radial hemostasis with the Axiostat® dressing was 78.0%. Procedural details and patient characteristics were comparable between successful Axiostat® removal and device failure cases.
CONCLUSION: The use of the Axiostat® dressing to achieve hemostasis after TRCA is effective but is associated with an unexpectedly high incidence of radial thrombosis. Our results should encourage caution in the future evaluation and use of this device for radial artery compression following TRCA.
The present invention relates to a medicinal composition for treating myopia and amblyopia and a preparation method thereof. The medicinal composition for treating myopia and amblyopia is composed of bear gall, pearl, hollow wood, safflower, Shiyanshi, calamine, jade slip and blade and borneol. The preparation method of the medicinal composition for treating myopia comprises the selection of raw materials, cleaning, baking, heating and concentration. The present invention has the advantages that the medicinal composition for treating myopia and amblyopia is put in a cucurbit-shaped device for the treatment of myopia for heating, the cucurbit-shaped device for the treatment of myopia is worn on eyes, medicinal steam which is emitted is used for fumigating the eyes. Because the medicinal composition for treating myopia and amblyopia has the functions of removing liver-fire for improving eyesight, activating blood circulation to dissipate blood stasis, improving the microcirculation of the eyes and recovering the elasticity of ciliary muscles of the eyes, the cure rate of myopia and amblyopia can be up to more than 85%, and the cure rate of early-stage cataract can be up to 57%. The effective rate of the present invention can be up to 80%.
Half the participants will receive topiramate and half will receive placebo. Neither participants nor study staff will know who is receiving which pills until the end of the study. Subjects will receive placebo pills identical to the active pills (pills that contain the study drug, topiramate) for the 12 treatment weeks of the study and will have the pills discontinued over the next four weeks of the study. All subjects will be re-evaluated at 26 and 52 weeks.
Ten percent of the population worldwide suffers from chronic kidney disease (CKD), but the mechanisms driving CKD pathology are incompletely understood. While dysregulated lipid metabolism is one hallmark of CKD, the pathogenesis of cellular lipid accumulation remains unclear. In this issue of the JCI, Mukhi et al. Identify acyl-CoA synthetase short-chain family 2 (ACSS2) as a disease risk gene and demonstrate a role for ACSS2 in de novo lipogenesis (DNL). Notably, genetic or pharmacological inhibition of DNL protected against kidney disease progression in mice. These findings warrant evaluation of DNL inhibition with respect to efficacy and safety in people with CKD.
Type 2 diabetic patients with previous coronary artery disease. All patients are routinely treated with aspirin in secondary prevention of cardiovascular disease. Coronary artery disease is defined as a previous coronary angiography with at least 1 coronary artery stenosis \>50%. Type 2 diabetes is defined as patients with diabetes discovered after 30 years old and insulin was not the first treatment except in case of acute coronary syndrome.
Filial piety is viewed as strong family support for older Chinese people, and strongly associated with depressive symptoms. It is unknown if there exists gender difference in the mediation effects of filial piety on the relationship between chronic obstructive pulmonary disease (manifested as lung function) and depression. We investigated whether filial piety mediates the association between lung function and depression in community-dwelling older men and women using the Healthy Aging Longitudinal Study in Taiwan (HALST). Community dwelling adults aged 65 and above were analyzed. Pulmonary function, depressive symptoms, and filial piety expectation (FPE) and receipt of filial piety (RFP) were collected. The interaction and mediation of filial piety between lung function and depression was analyzed. We found that in older men, forced expiratory volume in the first second (FEV1) was inversely correlated with depression (β = -0.1281, p = 0.004) with no mediation effect of FPE. In older women, FEV1 was negatively associated with FPE, but FPE did not increase the risk of depression (β = 0.0605, p = 0.12). In both older men and women, FEV1 was negatively associated with RFP, while RFP reduced the risk of depression (p< 0.001). In older women, the correlation between FEV1 was complete mediation of RFP. Results indicate that feelings of insufficient filial piety may increase the likelihood of depression, especially in elderly women with worse lung function. Although modest, the main mediation effect of filial piety was improvement of lung function in older subjects, which might decrease depression.
Depending on whether 1) child has had previous medication trial or 2) is on psychotropic medication at time of screening, children will either enter the washout period of 3 days before extended release mixed amphetamine salts (XR-MAS) or placebo (PBO) is initiated or proceed directly to the active treatment sequence they were randomized to. Participants randomized to Sequence 1 first receive treatment with XR-MAR for 3 weeks and then placebo for 3 weeks. Flexible, forced dosing will start at 5 mg/day for the first week, increase to 10 mg/day for the second week and continue to 15 mg/day on the third week. No washout period otherwise occurs (XR-MAS is not clinically suspected to have lingering effects beyond initial dosing/day of administration), including the crossover week to PBO.
The present invention relates to a method for preparing soymilk tablets with micron ash tree frondosa powder and glossy ganoderma spore powder for anti-tumor mutation. Various kinds of traditional soymilk tablets are added with micron ash tree bee pollen, micron pine pollen, micron bee pollen, micron ganoderma powder, micron ganoderma spore powder, and oligose powder which are crushed into ultrafine powder by high-tech air stream, all kinds of raw material are combined and processed, and a soymilk tablet for anti-tumor mutation is obtained. The soymilk tablet has the obvious function of anti-tumour mutation, and simultaneously, the soymilk tablet has the efficiency for eliminating toxicant, servicing beauty, strengthening immunity, etc. Middle-age people and old people can obtain hundreds of kinds of nutrient substances, such as rich vitamins, minerals, active ferments, etc. Because the micron pine pollen, the micron ash tree bee pollen, etc. which are called as a jewelry for facial beautification, servicing beauty, preventing cancer and resisting cancer in the east are added, the soymilk tablet is good for digestive absorption by a human body, and the health care efficiency for eliminating toxicant, servicing beauty, strengthening immunity, etc. is intensified. Therefore, the soymilk tablet is a good anti-tumour mutation soymilk tablet product which is especially designed for middle-age people and old people all over the world and especially tumor patients after operations, has the Chinese characteristics and prevents recurrence.
OBJECTIVE: The exact effects of MEFV variants on inflammation are still under investigation, and reports on variants of unknown significance, particularly the E148Q variant, have been conflicting. Therefore, this study aims to investigate patients exhibiting E148Q heterozygosity, focusing on diagnoses and disease courses to assist physicians in interpreting the variant.
METHODS: Data of pediatric patients presenting to the Pediatric Rheumatology clinic between November 2016 and September 2023, exhibiting only E148Q heterozygosity in MEFV gene analysis, were extracted. Patients who were lost before 9 months of follow-up have been excluded to ensure the completion of initial diagnostic tests and evaluations.
RESULTS: Among the 119 patients with E148Q variant, the diagnoses were as follows: healthy, 51.3%; IgA vasculitis, 10.1%; Familial Mediterranean Fever (FMF), 7.6%; Periodic fever, Aphtous stomatitis, Pharyngitis, Adenitis (PFAPA), 6.7%; and other diagnoses, 19.3%. IgA vasculitis patients experienced articular, gastrointestinal, and renal involvement at rates of 91.7%, 58.3%, and 16.7%, respectively. Complete response, partial response, and no response to colchicine were 37.5%, 12.5%, and 50%, respectively, in PFAPA patients. All FMF patients responded to colchicine treatment resulting in reduced mean FMF episode counts in 6 months from 3.22 ± 0.92 to 0.56 ± 0.52.
CONCLUSIONS: The E148Q variant may amplify inflammation and modify disease courses. Patients with the E148Q variant experiencing typical FMF episodes should receive colchicine, but clinicians should exercise caution regarding alternative diagnoses. Additionally, the E148Q variant may increase acute phase reactants and disease severity in IgA vasculitis. However, to reach definitive conclusions on its treatment-modifying role in PFAPA, universal diagnosis and treatment response criteria should be adopted.
BACKGROUND AND AIMS: Residual or recurrent adenoma (RRA) detected during surveillance is the major limitation of EMR. The pathogenesis of RRA is unknown, although thermal ablation of the post-endoscopic resection defect (PED) margin reduces RRA. We aimed to identify a feature within the PED that could be associated with RRA.
METHODS: Between January 2017 and July 2020, detailed prospective procedural data on all EMR procedures performed at a single center were retrospectively analyzed. At the completion of EMR, the PED was systematically examined for features of incomplete mucosal layer excision (IME). This was defined as a demarcated area within the PED bordered by a white electrocautery ring and containing endoscopically identifiable features suggesting incomplete resection of the mucosa including lacy capillaries and/or visible fibers of the muscularis mucosae. Areas of IME were reinjected and re-excised by snare and submitted separately for blinded specialist GI pathologist review.
RESULTS: EMR was performed for 508 large nonpedunculated colorectal polyps (LNPCPs) (median size, 35 mm). In 10 PEDs (2.0%), an area of IME was identified and excised. Histopathologic examination of areas of suspected IME demonstrated muscularis mucosae in 9 of 10 (90%), residual lamina propria in 9 of 10 (90.0%), and residual adenoma in 5 of 10 (50.0%). No RRA was detected during follow-up after re-excision of IME.
CONCLUSIONS: We report the novel finding of IME within the PED after EMR of LNPCPs. IME may contain microscopic residual adenoma and therefore is a risk for RRA during follow-up. After completion of EMR, the PED should be carefully evaluated. If IME is found, it should be excised. (Clinical trial registration number: NCT01368289 and NCT02000141.).
Studies are lacking that evaluate early postoperative pain after all-soft-tissue quadriceps tendon anterior cruciate ligament reconstruction (ACLR), particularly in young patients. The purpose of this study was to investigate differences in early postoperative pain between adolescent patients undergoing ACLR with quadriceps tendon versus hamstring autograft. A retrospective review was performed of 60 patients (mean age, 15.6 ± 1.3 years) who underwent ACLR using either quadriceps tendon ( n  = 31) or hamstring ( n  = 29) autografts between January 2017 and February 2020. Intraoperative and postoperative milligram morphine equivalents (MMEs), postanesthesia care unit (PACU) length of stay and PACU pain scores were recorded. Pain scores and supplemental oxycodone use were recorded on postoperative days (POD) 1-3. Differences were compared between the two groups. There were no statistically significant differences in age, sex, body mass index or concomitant meniscus repairs between the two groups ( P  > 0.05). There were no statistically significant differences in intraoperative MMEs, PACU MMEs or PACU length of stay between groups ( P  > 0.05). There were no statistically significant differences in maximum PACU pain scores (3.7 ± 3.0 vs. 3.8 ± 3.2; P  = 0.89). Maximum pain scores on POD 1-3 were similar between groups ( P  > 0.05). There were no statistically significant differences in supplemental oxycodone doses between groups on POD 1-3 ( P  > 0.05). Adolescent patients undergoing ACLR with quadriceps tendon and hamstring autografts have similar pain levels and opioid use in the early postoperative period.
INTRODUCTION: Anosognosia, a neurological condition, involves a lack of awareness of one's neurological or psychiatric deficits. Anton Syndrome (AS), an unusual form of anosognosia, manifests as bilateral vision loss coupled with denial of blindness. This systematic review delves into 64 studies encompassing 72 AS cases to explore demographics, clinical presentations, treatments, and outcomes.
MATERIALS AND METHODS: The study rigorously followed PRISMA guidelines, screening PubMed, Google Scholar, and Scopus databases without timeframe limitations. Only English human studies providing full text were included. Data underwent thorough assessment, examining patient demographics, etiological variables, and treatment modalities.
RESULTS: Sixty-four studies met the stringent inclusion criteria. Examining 72 AS cases showed a median age of 55 (6 to 96 years) with no gender preference. Hypertension (34.7 %) and visual anosognosia (90.3 %) were prevalent. Stroke (40.3 %) topped causes. Management included supportive (30.6 %) and causal approaches (30.6 %). Improvement was seen in 45.8 %, unchanged in 22.2 %, and deterioration in 11.1 %. Anticoagulation correlated with higher mortality (p < 0.05).
DISCUSSION: AS, an unusual manifestation of blindness, stems mainly from occipital lobe damage, often due to cerebrovascular incidents. The syndrome shares features with Dide-Botcazo syndrome and dates back to Roman times. Its causes range from strokes to rare conditions like multiple sclerosis exacerbation. Accurate diagnosis involves considering clinical presentations and imaging studies, distinguishing AS from similar conditions.
CONCLUSION: This comprehensive review sheds light on AS's complex landscape, emphasizing diverse etiologies, clinical features, and treatment options. Tailored treatments aligned with individual causes are crucial. The study's findings caution against blanket anticoagulation therapy, suggesting a nuanced approach. Further research is pivotal to refine diagnostics and optimize care for AS individuals.
The participant in the intervention group will practice breathing control and self-talk with objectives for relaxation. The duration of training is 4-5 minutes in each session, 4 sessions per week for 1 month.
HIIT was set at \> 85% HRmax. Active recovery was set at 25-50 watts. Sessions were performed using cycle ergometry.
Up to 3 SC doses may be selected for Part 2 and each patient will be assigned a single SerpinPC dose level (and placebo). The dose for Part 2 will be determined from ongoing review of the Part 1 data. The dose in Part will not exceed 1.2 mg/kg, or the highest dose deemed safe from Part 1b.
An aqueous composition including silica particles with a particle size distribution and particle structure that improve the water retention and exchange characteristics of the aqueous composition is provided. The aqueous silica composition includes silica network particles and water. The silica network particles comprise main particles and bridging particles that form chains between adjacent main particles. The main particles have a particles' size greater than the particle size of the bridging particles. Because of the presence of the silica network particles, the aqueous composition is capable of wetting a hydrophobic substrate more than pure liquid water. The silica network particles are generated in water by a method in which an aqueous sodium silicate solution is subjected to vigorous agitation in air (17), followed by periods of circulation through magnetic fields of alternating direction (30) and further periodic agitation exposed to the air (60).
NEW MATERIAL:A 2-arylimino-1,3-dithiolan derivative shown by formula I (R<1> is halogen, nitro, trifluoromethyl, hydroxyl group, mercapto, lower alkoxy or lower alkylthio; R<2> is alkyl). EXAMPLE:N-(1,3-Dithiolan-2-indene)-2-hydroxy-5-pentylaniline. USE:Having excellent inhibitory action on blood platelet aggregation, useful as an antithrombotic agent. Further useful as a preventive and remedy for various diseases caused by blood platelet aggregation such as thrombosis, atherosclerosis, etc. PREPARATION:For example, as shown by the reaction formula, a compound shown by formula II is reacted with methyl(1,3-dithiolan-2-indene)sulfonium iodide shown by the formula III in an organic base such as triethylamine, etc. at 15-40 deg.C to give a compound shown by formula I.
PURPOSE:To obtain the title preventive and remedy having no problems of occurrence of resistant bacteria and side effects and no fear of influence of remaining agent on human body, comprising a crude drug such as root and rhizome of Glycyrrhiza glabra Linne var. glandulifera Regel et Herder, leaves of Artemlsia princeps Pampanini or rhizome of Coptis japonica Makino as an active ingredient. CONSTITUTION:The title preventive and remedy comprising a crude drug selected from the group consisting of root and rhizome of Glycyrrhiza glabra Linne var. glandulifera Regel et Herder, leaves of Artemlsia princeps Pampanini, rhizome of Coptis japonica Makino, root of Scutellarla baicalensis Georgi, bark of Phellodendron amurense Ruprecht, stems and leaves of Geranium nepalense Sweet, bark of Magnolia obovata Thumberg, root of Salvia milltiorrhiza Bunge, rhizome of Rheum palmatum Linne, rhizome of Anemanhena asphodeloides Bunge, bud of Eugenia caryophyllata Thumb., fruit of Ligustrum japonicum Thunberg, 3-5mm cut pieces of ground part of Nepeta japonica Maximovicz, dried bark of Cinna momum Cassla Blume, root of Scrophularia Oldhami Oliver, ripe seed of Cassia obtusifolla Linne, leaves of Eribotrya japonica bindley, root and rhizome of Seselilibanotic Koch var. daucifolla DC., fruit ear of Humulus Lupulus Linne, Leaves of Perilla frutescens Britton var. acuta Kudo, bark of Myrica rubra Siebold et Zuccarini, fruit of Forsythia suspensa Vahl, Aloe arborescens Mill.
Risk Summary

Based on findings in animal reproduction studies and its mechanism of action, BEIZRAY can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1)] . Available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. BEIZRAY contains alcohol which can interfere with neurobehavioral development [see Clinical Considerations]. In animal reproductive studies, administration of docetaxel to pregnant rats and rabbits during the period of organogenesis caused an increased incidence of embryo-fetal toxicities, including intrauterine mortality, at doses as low as 0.02 and 0.003 times the recommended human dose based on body surface area, respectively [see Data]. Advise pregnant women and females of reproductive potential of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, miscarriage, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. 

Clinical Considerations

BEIZRAY contains alcohol [see Warnings and Precautions ( 5.13)] . Published studies have demonstrated that alcohol is associated with fetal harm including central nervous system abnormalities, behavioral disorders, and impaired intellectual development. 

Data

Animal data

Intravenous administration of ≥ 0.3 and 0.03 mg/kg/day docetaxel to pregnant rats and rabbits, respectively, during the period of organogenesis caused an increased incidence of intrauterine mortality, resorptions, reduced fetal weights, and fetal ossification delays. Maternal toxicity was also observed at these doses, which were approximately 0.02 and 0.003 times the daily maximum recommended human dose based on body surface area, respectively.